OMERACT Outcome Measures in Rheumatology	Summary of Measurement Properties Table

Instrument studied (& version): AUSCAN function

Background and target use

Target Domain:	Physical function	**Dates & initial assessment**			
Definition:		**Working Group signoff:**		**Review:**	
		Truth (domain match)	endorsed	**start**	**end**
		Feasibility			March 7 2020

Target Population:	**Intervention(s):**	**Control:**	**Desired use:**
Patients with hand osteoarthritis	All pharmacological and non-pharmacological interventions targeting symptom or structure modification	Placebo or standard care	Clinical trials of symptom or structure modification, or observational studies

Review findings*

Source		**Truth**		**Discrimination**			
Author, ref	**Year**	Construct validity	Inter-method reliability	Test- retest reliability	Longitudinal construct validity†	Clinical trial discrimination	Thresholds of meaning
Allen	2006	+					
Bellamy	2002	+		+		+	
Dziedzic	2007	+		+			
Fernandes	2012				+		
Haugen	2011						
Moe	2010	+		+			
Sautner	2009	+					
Stamm	2007	+					
Wittoek	2009	+					
Altman	2009					+	
Grifka	2004					+	
Keen	2010					+	
Bijsterbosch	2011				+		
Botha-Scheepers	2009				+		
Haugen	2013				+		
Marshall	2013				+		
Dilek	2013					+	
Brosseau	2005					+	
Kjeken	2011					±	
Bellamy	2007						+
Bellamy	2015						+
Siviero	2019						+
Kroon	2019					+	
Hand OA working group, unpublished							+
Synthesis							
Studies per property (n)		8		4	5	8	4
used in synthesis		7		3	5	8	4
Synthesis statement per property‡		**AMBER**		**GREEN**	**AMBER**	**GREEN**	**GREEN**
OMERACT Endorsement¶		**Based on these findings & the OMERACT algorithm, this instrument is:**					
Date ratified:		**Provisionally Endorsed.**					
		Optional to use as second measure of function, due to good measurement properties. However, due to feasibility (not available in public domain, costs associated with use of questionnaire), not recommended as mandatory instrument to measure function in all studies.					